Amid an industrywide kickbacks investigation into pharma's charity contributions, Gilead Sciences has become the latest drugmaker to strike a deal. Though the company says it doesn't believe it violated any laws, it agreed to pay $97 million to resolve kickbacks allegations.
Gilead is the latest drugmaker to strike a deal in the yearslong probe, following settlements of various sizes for Sanofi, Pfizer, Astellas, Amgen, Alexion and United Therapeutics, among others.
Read the source article at Pharma News
